Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Liabilities (2019 - 2021)

Historic Other Non-Current Liabilities for Keros Therapeutics (KROS) over the last 3 years, with Q3 2021 value amounting to $16000.0.

  • Keros Therapeutics' Other Non-Current Liabilities fell 7922.08% to $16000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $16000.0, marking a year-over-year decrease of 7922.08%. This contributed to the annual value of $62000.0 for FY2020, which is 4789.92% down from last year.
  • Latest data reveals that Keros Therapeutics reported Other Non-Current Liabilities of $16000.0 as of Q3 2021, which was down 7922.08% from $32000.0 recorded in Q2 2021.
  • In the past 5 years, Keros Therapeutics' Other Non-Current Liabilities registered a high of $119000.0 during Q4 2019, and its lowest value of $16000.0 during Q3 2021.
  • Over the past 3 years, Keros Therapeutics' median Other Non-Current Liabilities value was $69500.0 (recorded in 2020), while the average stood at $68500.0.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 4789.92% in 2020, then crashed by 7922.08% in 2021.
  • Keros Therapeutics' Other Non-Current Liabilities (Quarter) stood at $119000.0 in 2019, then crashed by 47.9% to $62000.0 in 2020, then crashed by 74.19% to $16000.0 in 2021.
  • Its Other Non-Current Liabilities stands at $16000.0 for Q3 2021, versus $32000.0 for Q2 2021 and $47000.0 for Q1 2021.